|By Marketwired .||
|September 12, 2008 09:00 AM EDT||
HUNTINGTON STATION, NY -- (Marketwire) -- 09/12/08 -- Medivisor, Inc. (PINKSHEETS: MVSR) announced today that Albumax has been approved by the New York State Medicaid Office. Albumax has been approved under code B4155 as an enteral product. The approval is significant in that it allows for Medicaid reimbursement of costs for eligible patients using Albumax. Medicaid is the largest source of funding for medical and health-related services for people with limited income. It is an entitlement program that is jointly funded by the states and federal government, and is managed by the states. Among the groups of people served by Medicaid are eligible low-income parents, children, seniors, and people with disabilities.
"Medicaid approval is an extremely important component in our marketing initiative for the national launch of Albumax," said Mr. Dino Luzzi, CEO of Medivisor, Inc. "Medicaid acceptance for Albumax certainly strengthens the interest in the product, and increases the willingness of providers and patients to use Albumax to increase blood albumin levels in kidney disorder patients," continued Mr. Luzzi. An important component of the overall initiative for Albumax is a very aggressive Internet marketing program that consistently keeps Albumax in the marketplace. Patients and those in the Medical Profession can now go to www.albumax.net to order or inquire about the product.
Under a recently announced agreement with Cura Pharmaceutical Co., Inc., Medivisor is responsible for marketing and sales of Albumax, a whey protein isolate formula that makes it easy for kidney disorder patients to reach their daily requirements of high quality protein in their diet.
About Medivisor, Inc.
Medivisor, Inc., a rapidly growing developer of next-generation focus driven marketing tools. The company is dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets and beyond. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of its clients. www.medivisor.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.
326 Walt Whitman Road
Huntington Station, N.Y. 11746
Aug. 28, 2015 06:00 AM EDT Reads: 350
Aug. 28, 2015 04:45 AM EDT Reads: 421
Aug. 28, 2015 04:30 AM EDT Reads: 321
Aug. 28, 2015 03:15 AM EDT Reads: 311
Aug. 28, 2015 03:00 AM EDT Reads: 336
Aug. 28, 2015 12:30 AM EDT Reads: 330
Aug. 28, 2015 12:00 AM EDT Reads: 377
Aug. 27, 2015 06:15 PM EDT Reads: 382
Aug. 27, 2015 05:45 PM EDT
Aug. 27, 2015 05:45 PM EDT Reads: 437
Aug. 27, 2015 04:15 PM EDT
Aug. 27, 2015 02:45 PM EDT Reads: 381
Aug. 27, 2015 02:15 PM EDT Reads: 510
Aug. 27, 2015 02:15 PM EDT
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.
Aug. 27, 2015 01:00 PM EDT Reads: 286